Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model

Antibody drug conjugates (ADC) are one of the attractive modalities for the treatment of acute myeloid leukemia (AML). Previously, we have developed ASP1235, a novel ADC targeting Fms-like tyrosine kinase 3 (FLT3) which is widely expressed on the leukemic blasts of AML patients. In this study, we so...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuzuki, Hirofumi, Kawase, Tatsuya, Nakazawa, Taisuke, Mori, Masamichi, Yoshida, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765856/
https://www.ncbi.nlm.nih.gov/pubmed/36537913
http://dx.doi.org/10.18632/oncotarget.28331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765856/
https://www.ncbi.nlm.nih.gov/pubmed/36537913
http://dx.doi.org/10.18632/oncotarget.28331

Ejemplares similares